Last reviewed · How we verify

NCT06592716

Can Recurrence of Cancer in the Oropharynx be Detected by Blood Samples?

Active, enrolled Last updated 18 November 2025
What this trial tests

trial testing Liquid biopsy in Oropharynx Cancer in 200 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
2 April 2024
Primary endpoint
31 December 2028
31 December 2028

Quick facts

Lead sponsorRigshospitalet, Denmark
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment200
Start date2 April 2024
Primary completion31 December 2028
Estimated completion31 December 2028
Sites1 location across Denmark

Drugs / interventions tested

Conditions studied

Sponsor

Rigshospitalet, Denmark

Who can join

18 and older, any sex, with Oropharynx Cancer or Oropharynx Cancer, Metastatic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study investigates if longitudinal analyses of cell-free HPV-DNA in blood samples can be utilized to detect recurrence in patients diagnosed and treated for HPV-positive oropharyngeal squamous cell carcinoma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Liquid biopsy

Trials testing the same drug.

Other recruiting trials for Oropharynx Cancer

Currently open trials in the same condition.

Other Rigshospitalet, Denmark trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06592716.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing